MedPath

Exosome Diagnostics, Inc.

Exosome Diagnostics, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
2008-01-01
Employees
51
Market Cap
-
Website
http://www.exosomedx.com

Clinical Trials

9

Active:0
Completed:3

Trial Phases

1 Phases

Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (100.0%)

ExoDx Prostate Evaluation in Active Surveillance Patient Population

Recruiting
Conditions
Prostate Cancer
First Posted Date
2022-10-07
Last Posted Date
2022-10-07
Lead Sponsor
Exosome Diagnostics, Inc.
Target Recruit Count
750
Registration Number
NCT05572099
Locations
🇺🇸

Chesapeake Urology, Towson, Maryland, United States

Urine Biomarker for Kidney Transplant Rejection

Not yet recruiting
Conditions
Graft Rejection
First Posted Date
2021-10-11
Last Posted Date
2021-10-11
Lead Sponsor
Exosome Diagnostics, Inc.
Target Recruit Count
750
Registration Number
NCT05072951

Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy

Completed
Conditions
Urologic Cancer
First Posted Date
2021-01-22
Last Posted Date
2021-09-30
Lead Sponsor
Exosome Diagnostics, Inc.
Target Recruit Count
120
Registration Number
NCT04720599
Locations
🇺🇸

Chesapeake Urology Research Associates, Baltimore, Maryland, United States

🇺🇸

New Jersey Urology, Voorhees, New Jersey, United States

🇩🇪

Klinikum der Universität München, München, Germany

ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting

Terminated
Conditions
Prostate Cancer
First Posted Date
2020-04-22
Last Posted Date
2022-03-31
Lead Sponsor
Exosome Diagnostics, Inc.
Target Recruit Count
150
Registration Number
NCT04357717
Locations
🇺🇸

Chesapeake Urology Research Associates, Baltimore, Maryland, United States

🇺🇸

New Jersey Urology, Voorhees, New Jersey, United States

Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients

Conditions
Carcinoma, Non-Small-Cell Lung
First Posted Date
2017-08-02
Last Posted Date
2021-09-30
Lead Sponsor
Exosome Diagnostics, Inc.
Target Recruit Count
60
Registration Number
NCT03236675
Locations
🇺🇸

Memorial Healthcare System, Hollywood, Florida, United States

🇺🇸

Ochsner Medical Center, New Orleans, Louisiana, United States

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.